Acorda Therapeutics
ACOR
#8336
Rank
$0.82 M
Marketcap
$0.66
Share price
0.00%
Change (1 day)
37.71%
Change (1 year)

P/E ratio for Acorda Therapeutics (ACOR)

P/E ratio as of April 2024 (TTM): -0.0676

According to Acorda Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0676042. At the end of 2022 the company had a P/E ratio of -0.0087.

P/E ratio history for Acorda Therapeutics from 2006 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-0.0087-27.09%
2021-0.0120-31.16%
2020-0.0174-1.94%
2019-0.0177-101.64%
20181.08-588.26%
2017-0.2216-82.08%
2016-1.24-115.03%
20158.2373.11%
20144.7533.46%
20133.561023.01%
20120.3171-79.52%
20111.55-137.48%
2010-4.13627.72%
2009-0.567621.21%
2008-0.4683-38.16%
2007-0.7572336.94%
2006-0.1733

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-14.9 21,918.01%๐Ÿ‡บ๐Ÿ‡ธ USA
75.1-111,259.22%๐Ÿ‡บ๐Ÿ‡ธ USA
-6.42 9,391.91%๐Ÿ‡ฉ๐Ÿ‡ช Germany
116-171,203.27%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.